Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 14/20 | 1.00 |
| ▸ | BCR | P11274 | 12/20 | 1.00 |
| ▸ | PRKCA | P17252 | 3/20 | 0.73 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.68 |
| ▸ | EGFR | P00533 | 5/20 | 0.67 |
| ▸ | SRC | P12931 | 1/20 | 0.67 |
| ▸ | PRKACA | P17612 | 1/20 | 0.67 |
| ▸ | PRKACG | P22612 | 1/20 | 0.67 |
| ▸ | PRKACB | P22694 | 1/20 | 0.67 |
| ▸ | JAK3 | P52333 | 1/20 | 0.63 |
| ▸ | BTK | Q06187 | 1/20 | 0.63 |
| ▸ | ITK | Q08881 | 1/20 | 0.63 |
| ▸ | KIT | P10721 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29555505 | 1.00 | ABL1 (1.00) | ABL1BCRPRKCAPDGFRAPDGFRB | |
| SCHEMBL29366999 | 1.00 | ABL1 (1.00) | ABL1BCRPRKCAPDGFRAPDGFRB | |
| Ammonia Solution, Strong SCHEMBL4749564 | 0.99 | ABL1 (0.98) | ABL1BCRPRKCAPDGFRAPDGFRB | |
| Hydrochloric Acid SCHEMBL2419016 | 0.99 | ABL1 (0.98) | ABL1BCRPRKCAPDGFRAPDGFRB | |
| SCHEMBL14938216 | 0.92 | ABL1 (0.85) | ABL1BCRPRKCAPDGFRAPDGFRB | |
| SCHEMBL3860532 | 0.91 | ABL1 (0.83) | ABL1BCRPRKCAPDGFRAPDGFRB | |
| SCHEMBL2575958 | 0.88 | ABL1 (0.78) | ABL1BCRPRKCAPDGFRAPDGFRB | |
| SCHEMBL12320924 | 0.88 | ABL1 (0.78) | ABL1BCRPRKCAPDGFRAPDGFRB | |
| SCHEMBL7601457 | 0.88 | ABL1 (0.78) | ABL1BCRPRKCAPDGFRAPDGFRB | |
| SCHEMBL14041906 | 0.87 | ABL1 (0.78) | ABL1BCRPRKCAPDGFRAPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 560 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112125882-B | Method for synthesizing imatinib free base | 山东汇海医药化工有限公司 | 2023-04-11 | — | — | CN | claimed |
| CN-111440147-B | Synthesis method of N- (2-methyl-5-aminophenyl) -4- (3-pyridyl) -2-pyrimidinamine | 苏州卫生职业技术学院 | 2023-03-07 | — | — | CN | claimed |
| CN-114685428-A | Preparation method of imatinib mesylate | 重庆圣华曦药业股份有限公司 | 2022-07-01 | — | — | CN | claimed |
| CN-110078706-B | Imatinib derivative and preparation method and application thereof | 浙江师范大学 | 2022-02-01 | — | — | CN | claimed |
| CN-112125882-A | Method for synthesizing imatinib free base | 山东汇海医药化工有限公司 | 2020-12-25 | — | — | CN | claimed |
| CN-111440147-A | Synthesis method of N- (2-methyl-5-aminophenyl) -4- (3-pyridyl) -2-pyrimidinamine | 苏州卫生职业技术学院 | 2020-07-24 | — | — | CN | claimed |
| CN-107089969-B | Method for synthesizing imatinib intermediate | 黑龙江鑫创生物科技开发有限公司 | 2020-04-24 | — | — | CN | claimed |
| CN-111039921-A | Synthesis process of imatinib and imatinib mesylate | 杭州沧海帆医药科技有限公司 | 2020-04-21 | — | — | CN | claimed |
| WO-2018204829-A1 | METHODS FOR PREVENTING NEURAL TUBE DEFECTS IN DIABETIC PREGNANCY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2018-11-08 | — | — | WO | claimed |
| EP-2608791-B1 | A PROCESS FOR THE PREPARATION OF IMATINIB BASE | MUSTAFA NEVZAT ILAC SANAYII A S (TR) | 2016-05-18 | — | — | EP | claimed |
| WO-2007067629-A1 | BRADYKININ 1 RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 2007-06-14 | — | — | WO | claimed |
| EP-1721609-A2 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC Biotech AG (DE) | 2006-11-15 | — | — | EP | claimed |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2006-09-28 | — | — | US | claimed |
| WO-2006071130-A2 | A PROCESS FOR PREPARATION OF IMATINIB BASE | INSTYTUT FARMACEUTYCZNY (PL) | 2006-07-06 | — | — | WO | claimed |
| US-20060149061-A1 | Novel process for preparing Imatinib | PERRIGO API LTD. (IL) | 2006-07-06 | — | — | US | claimed |
| EP-1395261-B1 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | GPC BIOTECH AG (DE) | 2006-06-28 | — | — | EP | claimed |
| WO-2004108699-A1 | PROCESS FOR THE PREPARATION OF THE ANTI-CANCER DRUG IMATINIB AND ITS ANALOGUES | NATCO PHARMA LIMITED (IN) | 2004-12-16 | — | — | WO | claimed |
| EP-1395261-A2 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2004-03-10 | — | — | EP | claimed |
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2003-09-18 | — | — | US | claimed |
| WO-2002093164-A2 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | AXXIMA PHARMACEUTICALS AG (DE) | 2002-11-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | PRNP, PPM1D, PPM1F | ABL1 901/4885BCR 1338/4885PRKCA 138/4885 |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | PRNP, PPM1D, PPM1F | ABL1 904/4885BCR 1230/4885PRKCA 121/4885 |
| US-20060149061-A1 | Novel process for preparing Imatinib | ABL1, ABL2, PDGFRA | ABL1 1/4885BCR 22/4885PRKCA 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.